WO2026047603 - SARS-COV-2 IMMUNOGENIC COMPOSITIONS
National phase entry is expected:
Publication Number
WO/2026/047603
Publication Date
05.03.2026
International Application No.
PCT/IB2025/058706
International Filing Date
28.08.2025
Title **
[English]
SARS-COV-2 IMMUNOGENIC COMPOSITIONS
[French]
COMPOSITIONS IMMUNOGÈNES CONTRE SARS-COV-2
Applicants **
BIONTECH SE
PFIZER INC.
Inventors
MUIK, Alexander
GÜLER, Alptekin
HOFMEISTER, Thomas
WILLMER, Moritz Willy Rudolf
GALEEV, Alibek
LINDEMANN, Claudia
CHE, Ye
CAI, Hui
MODJARRAD, Kayvon
MUNASINGHE, Aravinda
SWANSON, Kena Anne
WINDSOR, Ian William
WU, Huixian
Priority Data
63/688,279
28.08.2024
US
63/700,480
27.09.2024
US
63/754,514
05.02.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9926 | |
| EPO | Filing, Examination, Granting | 30756 | |
| Japan | Filing, Examination, Granting | 2400 | |
| South Korea | Filing, Examination, Granting | 2538 | |
| USA | Filing, Examination, Granting | 10540 |
Total:
56,160
Contact Us
Abstract[English]
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and/or overcome immune imprinting in SARS-CoV-2.[French]
Sont divulgués des compositions comprenant des antigènes protéiques et de l'ARN les codant (par exemple, des compositions comprenant des antigènes protéiques et de l’ARN codant les antigènes) qui peuvent être utilisés pour induire une réponse immunitaire contre le SARS-CoV-2. Sont divulguées également des compositions immunogènes et des préparations médicales les comprenant, ainsi que leurs procédés de fabrication et d'utilisation. Dans certains modes de réalisation, les technologies selon l'invention peuvent être utilisées pour traiter et/ou surmonter l'empreinte immunitaire du SARS-CoV-2.